Your browser doesn't support javascript.
loading
Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II.
He, Xiujing; Xu, Jie; Meng, Huan; Shi, Hubing.
Affiliation
  • He X; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.
  • Xu J; Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
  • Meng H; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology, Beijing, China.
  • Shi H; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.
Front Pharmacol ; 13: 1106129, 2022.
Article in En | MEDLINE | ID: mdl-36588733
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: China Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: China Country of publication: Switzerland